AN2 Therapeutics, Inc.
ANTX
$5.67
-$0.32-5.27%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.89M | 3.81M | 2.44M | 3.04M | 4.02M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.90M | 10.55M | 9.32M | 10.04M | 7.22M |
| Operating Income | -8.90M | -10.55M | -9.32M | -10.04M | -7.22M |
| Income Before Tax | -8.19M | -10.03M | -8.71M | -9.35M | -6.46M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.19M | -10.03M | -8.71M | -9.35M | -6.46M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.19M | -10.03M | -8.71M | -9.35M | -6.46M |
| EBIT | -8.90M | -10.55M | -9.32M | -10.04M | -7.22M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.18 | -0.29 | -0.29 | -0.31 | -0.21 |
| Normalized Basic EPS | -0.11 | -0.18 | -0.18 | -0.19 | -0.13 |
| EPS Diluted | -0.18 | -0.29 | -0.29 | -0.31 | -0.21 |
| Normalized Diluted EPS | -0.11 | -0.18 | -0.18 | -0.19 | -0.13 |
| Average Basic Shares Outstanding | 44.76M | 34.06M | 30.36M | 30.28M | 30.17M |
| Average Diluted Shares Outstanding | 44.76M | 34.06M | 30.36M | 30.28M | 30.17M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |